NuCana PLC
NASDAQ:NCNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
TOT BIOPHARM International Co Ltd
HKEX:1875
|
CN |
|
ATN International Inc
NASDAQ:ATNI
|
US |
|
Easyjet PLC
LSE:EZJ
|
UK |
|
Sunny Optical Technology Group Co Ltd
HKEX:2382
|
CN |
|
Biogaia AB
STO:BIOG B
|
SE |
|
ITI Ltd
NSE:ITI
|
IN |
|
J
|
Jiangsu Hongdou Industrial Co Ltd
SSE:600400
|
CN |
|
Xiaomi Corp
HKEX:81810
|
CN |
NuCana PLC
Other Items
NuCana PLC
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NuCana PLC
NASDAQ:NCNA
|
Other Items
£352k
|
CAGR 3-Years
-18%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Other Items
-£12m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Other Items
£6.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Other Items
-£962k
|
CAGR 3-Years
71%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
NuCana PLC
Glance View
NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. The firm is focused on developing treatments for cancer patients using its ProTide technology. ProTide are designed to overcome cancer resistance mechanism and generate anti-cancer metabolites in cancer cells. The firm's pipeline includes Acelari, NUC-3373, and NUC-7738. Its ProTide candidates Acelari and NUC-3373 are chemical entities derived from the nucleotide analog and 5- fluorouracil, which are used as chemotherapy agents for the treatment of cancer. Acelari is in a Phase III study for patients with biliary tract cancer. NUC-3373 is in Phase I study for the treatment of a range of patients with solid tumors and a Phase I b study for patient with metastatic colorectal cancer. Its third ProTide candidate, NUC-7738, is a nucleotide analog (3’-deoxyadenosine) and is in Phase I study for patients with solid tumors.
See Also
What is NuCana PLC's Other Items?
Other Items
352k
GBP
Based on the financial report for Dec 31, 2025, NuCana PLC's Other Items amounts to 352k GBP.
What is NuCana PLC's Other Items growth rate?
Other Items CAGR 5Y
2%
Over the last year, the Other Items growth was -5%. The average annual Other Items growth rates for NuCana PLC have been -18% over the past three years , 2% over the past five years .
